



Industry Sponsored Sessions – Wednesday, Sept. 4, 2019

ROOM: HUBERT VAN EYCK

12:45 – 13:55 Levosimendan in cardiac surgery: tying up loose ends

With an unrestricted grant by Orion Pharma

Chairmen: D. Bettex; P. Wouters ; F. Guarracino

12:45-13:05 Pre-operative levosimendan in isolated CABG patients at risk of LCOS – M. Heringlake

13:05-13:08 Rapid fire: Limitations – P. Gaudard

13:08 -13:11 Rapid fire: Expectations – W. Toller

13:11-13:31 Peri-operative levosimendan in clinical practice: when and why? Should kidney function be considered? – S. Bouchez

13:31-13:34 Rapid fire: Limitations – S. Rex

13:34-13:37 Rapid fire: Expectations – G. Paternoster

13:37-13:52 Take home message “Levosimendan in cardiac surgery: safety and efficacy after 20 years” – D. Bettex

13:52-13:55 Wrap-up – P. Wouters, F. Guarracino

ROOM: VAN DER GOES

12:45 – 13:55 Is aprotinin safe? Registry data from 2016-2019 in EU

With an unrestricted grant by Nordic Pharma

Speakers: K. Zacharowski, S. De Hert, A. Ouattara

ROOM: BAEKELAND 3

12:45 – 13:55 Leading cardiac innovation to improve patient outcome

With an unrestricted grant by EDWARDS

12:45-13:05 Swan-Ganz - what can you expect from a daily usage – S. Rex

13:05-13:25 Cardiac ERAS – evolving hemodynamic optimization in cardiac surgery – T.E. Perry

13:25-13:40 Monitoring heart - brain interaction - leveraging cerebral oximetry for actionable insights – A. Denault

13:40-13:55 The future is here – identifying and treating hypotension with predictive analytics – T. Scheeren